Alexion's Rare Bone Drug Strensiq 'Not Value For Money'
This article was originally published in Scrip
Executive Summary
NICE, the HTA body for England and Wales, has issued draft guidance that does not recommend Alexion's rare bone disease treatment Strensiq (asfotase alfa) for pediatric-onset hypophosphatasia.